Trial Objectives
Idiopathic pulmonary fibrosis (IPF) currently affects millions of people globally, and current treatments such as pirfenidone or nintedanib are often poorly tolerated in some patients due to frequently associated side effects. Researchers want to know if an investigational medication called BBT-877, either alone or in conjunction with other therapies, may help slow lung function decline.
In this study, participants 40 and older with IPF will receive either BBT-877 or the placebo that does not contain any medication twice a day.
Who Can Participate
Adults aged 40 and older with a documented IPF diagnosis, who are not current smokers and do not have a history of conditions that increase risk (prior lung transplant, pulmonary hypertension, immunosuppressive condition or congestive heart failure). Participants must not be taking background antifibrotic medication, or they must have been on an antifibrotic (nintedanib or pirfenidone) for at least three months.
Age: 40+ Gender: Any
Estimated Time Commitment
Six clinic visits over up to 34 weeks
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Elizabeth Del Real
303-398-1172
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Bridge Biotherapeutics, Inc
Principal Investigators
Jeff Swigris, DO, MS
